Takeda navigates Vyvanse patent cliff with cost cuts, pipeline gains
Takeda Pharmaceutical (NYSE:TAK) reported fiscal year 2025 results that met its revised management guidance, as the company utilized aggressive operational savings to buffer the impact of generic competition for its top-selling ADHD medication, Vyvanse.










